MARKET

CRIS

CRIS

Curis
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.7067
-0.0628
-8.16%
Closed 16:00 05/24 EDT
OPEN
0.7660
PREV CLOSE
0.7695
HIGH
0.7660
LOW
0.7010
VOLUME
1.28M
TURNOVER
584.47K
52 WEEK HIGH
15.60
52 WEEK LOW
0.7010
MARKET CAP
64.77M
P/E (TTM)
-1.2541
1D
5D
1M
3M
1Y
5Y
20 Stocks Moving in Friday's Pre-Market Session
Gainers Exicure, Inc. (NASDAQ: XCUR) shares rose 28.1% to $0.1550 in pre-market trading. Exicure said in Form4 filing a director bought 1,472,126 shares at average price of $0.19 per share.
Benzinga · 4d ago
Curis Announces Abstracts Accepted for Presentation at the European Hematology Association 2022 Congress (EHA)
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that multiple abstracts have been accepted for presentation at the upcoming European Hematology Associati...
PR Newswire · 05/12 14:26
10 Stocks to Invest in Under $20 According to Michael Castor’s Sio Capital
In this piece, we will take a look at the ten stocks to invest in under $20 according to Sio Capital. To skip the bottom five stocks in this list, head on over to 5 Stocks to Invest In Under $20 According to Michael Castor’s Sio Capital. Sio Capital is a h...
Insider Monkey · 05/11 12:59
Curis (CRIS) Reports Q1 Loss, Misses Revenue Estimates
Curis (CRIS) delivered earnings and revenue surprises of -5.88% and 6.71%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/05 22:05
Curis Q1 EPS $(0.18) Misses $(0.16) Estimate, Sales $2.10M Miss $2.40M Estimate
Curis (NASDAQ:CRIS) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.16) by 12.5 percent. This is a 63.64 percent decrease over losses of $(0.11) per share from the same
Benzinga · 05/05 20:37
Curis GAAP EPS of -$0.18 misses by $0.02, revenue of $2.06M misses by $0.49M
Curis press release (NASDAQ:CRIS): Q1 GAAP EPS of -$0.18 misses by $0.02. Revenue of $2.06M (-5.9% Y/Y) misses by $0.49M. Shares -2.2%.
Seekingalpha · 05/05 20:10
-- Earnings Flash (CRIS) CURIS Posts Q1 Revenue $2.1M, vs. Street Est of $2.55M
MT Newswires · 05/05 16:37
Earnings Outlook For Curis
Curis (NASDAQ:CRIS) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Curis will report an earnings per share (EPS) of $-0.16.
Benzinga · 05/04 19:20
More
No Data
Learn about the latest financial forecast of CRIS. Analyze the recent business situations of Curis through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
83.33%Buy
16.67%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average CRIS stock price target is 11.80 with a high estimate of 22.00 and a low estimate of 4.000.
High22.00
Average11.80
Low4.000
Current 0.7067
EPS
Actual
Estimate
-0.14-0.11-0.07-0.04
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 152
Institutional Holdings: 68.92M
% Owned: 75.21%
Shares Outstanding: 91.65M
TypeInstitutionsShares
Increased
50
14.39M
New
14
2.69M
Decreased
38
15.62M
Sold Out
21
8.34M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.05%
Pharmaceuticals & Medical Research
+0.25%
Key Executives
Non-Executive Chairman/Independent Director
Martyn Greenacre
President/Chief Executive Officer/Director
James Dentzer
Chief Financial Officer/Chief Administrative Officer
William Steinkrauss
Other
Robert Martell
Independent Director
John Hohneker
Independent Director
Kenneth Kaitin
Independent Director
Lori Kunkel
Independent Director
Marc Rubin
No Data
No Data
About CRIS
Curis, Inc. is a biotechnology company focused on the development of therapeutics for the treatment of cancer. The Company’s drug candidates include CA-4948 and CI-8993. CA-4948 is an orally available small-molecule inhibitor of Interleukin-I receptor-associated kinase 4, which is undergoing testing in a Phase I open-label dose escalating clinical trial in patients with non-Hodgkin lymphomas. It is also conducting a Phase I open-label, single-arm dose escalating trial in patients with acute myeloid leukemia, and myelodysplastic syndromes. CI-8993 is a monoclonal antibody designed to antagonize the V-domain Ig suppressor of the T cell activation signaling pathway. The Company initiated a Phase Ia/Ib trial of CI-8993 in patients with solid tumors. The Company’s products pipeline includes Fimepinostat, CA-170, CA-327, and PD1/TIM3 Program.

Webull offers kinds of Curis, Inc. stock information, including NASDAQ:CRIS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRIS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CRIS stock methods without spending real money on the virtual paper trading platform.